menu
    • menu
    [{"orgOrder":0,"company":"Junevity","sponsor":"Goldcrest Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Junevity","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Junevity \/ Goldcrest Capital","highestDevelopmentStatusID":"4","companyTruncated":"Junevity \/ Goldcrest Capital"},{"orgOrder":0,"company":"Junevity","sponsor":"Goldcrest Capital | Godfrey Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Financing","leadProduct":"JUN_01","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Junevity","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Junevity \/ Goldcrest Capital | Godfrey Capital","highestDevelopmentStatusID":"4","companyTruncated":"Junevity \/ Goldcrest Capital | Godfrey Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Junevity

    Menu

    Junevity

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Junevity

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Junevity

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JUN_01

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Goldcrest Capital | Godfrey Capital

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Junevity Boosts Seed Funding to $20M for Cell Reprogramming with siRNA

                            Details : The financing for JUN_01, an oligonucleotide product targeting Type 2 Diabetes, aims to advance research in this key focus area.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            December 03, 2025

                            Lead Product(s) : JUN_01

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Goldcrest Capital | Godfrey Capital

                            Deal Size : $20.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Junevity

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            Junevity

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Goldcrest Capital

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Junevity Raises $10M to Develop Cell Reset Therapeutics for Longevity

                            Details : The seed funding will enhance the RESET platform and develop company's first therapeutic candidates in Type 2 diabetes, obesity and frailty.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 13, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Goldcrest Capital

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth